Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ERODE: Ticagrelor in ACS with Plaque Erosion
NCT02041650Phase 4Completed
- Start
- Aug 2014
- Primary completion
- Apr 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of ticagrelor in acute coronary syndrome (ACS). Primary endpoint: Reduction of thrombus burden by OCT at 30 days. Started Aug 2014; status: completed.
02
Drugs
ticagrelor
03
Conditions
acute coronary syndrome (ACS)
Beyond the preview
Go deeper on NCT02041650.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02041650.